Steep Hill Inc.

Steep Hill Inc., a cannabis science and technology company, provides laboratory testing, quality assurance, and data analytics services in Canada and the United States. It offers analytical testing services, such as cannabinoids, terpenes, pesticides analysis, mycotoxins analysis, heavy metals analysis, residual solvents analysis, microbial analysis, foreign matter inspection, moisture content analysis, water activity analysis, vitamin E acetate, homogeneity testing, and hemp analysis, as well as consulting services in the areas of analytical testing, cannabis testing regulations, test methods, laboratory information management systems, and product quality and safety. The company was formerly known as Cannabis Clonal Corporation and changed its name to Steep Hill Inc. in February 2022. Steep Hill Inc. was founded in 2008 and is based in Toronto, Canada.

Steep Hill Inc. trades as STPH.CN on CNQ. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and $337,714 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Steep Hill Inc. can be compared against peers such as CENTR Brands Corp., Captor Capital Corp., TripSitter Clinic Ltd., Global Health Clinics Ltd., Optimind Pharma Corp., Ovation Science Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $160,317, beta of 1.73, and return on equity of +16.7%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

STPH.CN currently shows total debt of $0 and beta of 1.73. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.steephill.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.